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BACKGROUND: Mesenchymal stem cells (MSCs) are
multipotent stem cells. Based on their properties,
several clinical trials have been designed to explore
their potential therapeutic effect. Fetal calf serum (FCS,
commonly used for in vitro expansion) is an undesirable
source of xenogeneic antigens and bears the risk of
transmitting contaminations. As an alternative for FCS,
platelet lysate (PL) and both autologous and allogeneic
human serum have been proposed. The aim of this
study is to compare the culture of bone marrow (BM)-
derived MSCs in the presence of different serum
supplements to determine the effect on cell growth, dif-
ferentiation potential, and immunologic function.
STUDY DESIGN AND METHODS: MSCs from BM of
healthy volunteer donors were grown in the presence of
10% FCS supplemented with 1 ng/mL basic fibroblast
growth factor (bFGF), 10% human serum supplemented
with 1 ng/mL bFGF, 5% PL, and PL 5% supplemented
with 1 ng/mL bFGF (PL plus bFGF).
RESULTS: MSCs that expanded in either medium
showed a comparable morphology, phenotype, and pro-
liferative and differentiation capacity. While the pres-
ence of MSCs in vitro significantly decreased CD3/
CD28-mediated T-cell activation, this effect was
significantly higher in MSCs cultured with human
serum. Production of interferon-g was inhibited by co-
cultured media with MSCs while MSCs also induced a
significant inhibition of cell cycle in T cells.
DISCUSSION: In conclusion, PL or autologous serum
could offer an alternative to the use of FCS in MSC
expansion for clinical use maintaining the same growing
potential, phenotype, immunomodulatory properties,
and differentiation potential.
M
esenchymal stem cells (MSCs) aremultipo-
tent stem cells that can be recovered/
obtained from a variety of tissues such as
bone marrow (BM), cord blood, adipose
tissue, amniotic fluid, and so forth.1-3 MSCs are plastic
adherent in standard culture conditions.4 Phenotypically,
they express a number of nonspecific markers such as
CD105, CD73, and CD90; lack expression of hematopoi-
etic markers such as CD45, CD34, CD14 or CD11b, CD79a
or CD19, and HLA-DR;5,6 and can differentiate into osteo-
blasts, adipocytes, and chondrocytes.7 Based on their
immunomodulatory and regenerative properties, several
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clinical trials have been designed in an attempt to explore
their therapeutic potential in graft-versus-host disease
(GVHD), Chron disease, multiple sclerosis, diabetes, myo-
cardial infarction, cirrhosis, and osteogenesis imperfecta
(http://www.clinicaltrials.gov).
Remarkably, most clinical trials use BM-derived
MSCs (BM-MSCs) generated in a medium supplemented
with fetal calf serum (FCS). However, FCS is an undesir-
able source of xenogeneic antigens and bears the risk of
transmitting animal viral, prion, and zoonose contamina-
tions. As an alternative for FCS, platelet lysate (PL)8-12 and
both autologous and allogeneic human serum have been
proposed.13-15 The use of allogeneic human serum has
resulted in MSC growth arrest and death in some studies
while the use of autologous serum allows a faster prolif-
eration compared to FSC at least during the first passages
and, in addition, avoids the exposure to allogeneic anti-
gens and minimizes the risk of infection.13,15-17 Neverthe-
less, the amount of autologous serum required for a
sufficient expansion exceeds the amount a donor could
provide.We have previously reported amethod for obtain-
ing large amounts of autologous serum for in vitro culture
of human skeletal myoblasts at a clinical scale.18
The aim of this study is to compare culture medium
supplemented with FCS with alternative supplements
such as human serum and PL.We compared the effects of
different types of media on the yield of MSC cultures, pro-
liferation, and differentiation capacity as well as on their
immunologic properties.
MATERIALS AND METHODS
Isolation and culture of BM mononuclear cells
Human MSCs were isolated from the BM of healthy vol-
unteer donors after informed consent was obtained,
according to the local Ethics Committee at University of
Navarra. A total of 30 to 40 mL of BM was obtained by
multiple 2- to 3-mL aspirations from the iliac crest under
local anesthesia, according to standard institutional
procedures. The median age of BM donors was 20 years
(range, 19-21 years).
Mononuclear cells (MNCs) were isolated by a density
gradient centrifugation (Ficoll-Paque, GE Healthcare Bio-
Sciences, AB, Uppsala, Sweden). Briefly, 2 vol of BM was
added to 1 vol of Ficoll in a tube and centrifuged at 800 ¥ g
for 20 minutes. MNCs were resuspended and plated in
noncoated 75- to 175-cm2 polystyrene culture flasks
(Corning Costar, Celbio, Milan, Italy) in modified Eagle’s
medium-a (a-MEM [Gibco, Invitrogen, Paisley, UK]) with
1% penicillin/streptomycin (pen/strep; Gibco) at a con-
centration of 115,000 cells/cm2. Four different supple-
ments were tested:
1. 10% FCS (BioWhittaker, Lonza, Verviers, Belgium)
supplemented with 1 ng/mL basic fibroblast
growth factor (bFGF; Sigma, St Louis, MO; FCS
medium);
2. 10% human serum supplemented with 1 ng/mL
bFGF (HS medium) obtained by venipuncture;
3. 5% PL; and
4. PL 5% supplemented with 1 ng/mL bFGF (PL plus
bFGF).
To lyse the platelets (PLTs) different PLT apheresis col-
lectionswere discarded from the Blood Bank of the Clínica
UniversitariadeNavarraandwere frozenat-80°Cand then
thawed at 37°C to lysate the PLTs to obtain the released
growth factors. Samples were centrifuged at 900 ¥ g for 30
minutes todiscardPLTs. Supernatantwasusedasa supple-
ment and 10 IU of heparin per 5 mL ofmediumwas added
before use to avoid gel formation. Cellswere incubated in a
humidified atmosphere with complete medium replace-
ment twice a week. The first passage (P1) was performed
when cells reached a confluence of 70% to 80% (Days
10-15).MSCswere then replated at a concentrationof 1000
to 5000 cells/cm2 and passaged when a confluence of 80%
was reached (P2-P4). The number of cells and the duplica-
tion time was calculated after P1 to P4.
Characterization of MSCs
Immunophenotype
For fluorescence-activated cell sorter (FACS) analysis, the
following antibodies were used: CD34-allophycocyanin
(APC), CD44-fluorescein isothiocyanate (FITC), CD45-
peridinin chlorophyll protein (PerCP), CD73-
phycoerythrin (PE), and CD90-FITC (all from BD
PharMingen, San Diego, CA) and their corresponding
isotype controls (all from BD PharMingen). A total of
50,000 to 200,000 cells were incubated with primary anti-
body for 15minutes in the dark at room temperature. Cells
were fixed with 4% formaldehyde at 4°C. The analysis was
performed on a flow cytometer (FACSCalibur, Becton
Dickinson Biosciences, San Jose, CA). Calibration of the
instrument was performed before data acquisition using
previously well-established protocols.9 A software
program (CellQuest, Becton Dickinson Biosciences) was
used for the acquisition of 50,000 total cells. Data analysis
was performed using a computer program (Paint-A-Gate,
Becton Dickinson).
T-lymphocyte inhibition assay
MSCs expanded as previously specified and were cultured
in 48-well plates with T lymphocytes obtained from
healthy donors’ buffy coats by density gradient centrifuga-
tion, in a 1:10 (MSC : T-cell) ratio. Cells were cultured with
500 mL per well of RPMI 1640 supplemented with
2 mmol/L l-glutamine, 100 U/mL penicillin, 100 mg/mL
streptomycin (Gibco, Grand Island, NY) and 10% human
ABserum(Sigma). Foractivationassayswecultured3 ¥ 104
PÉREZ-ILZARBE ET AL.
2 TRANSFUSION Volume **, ** **
MSCs per well, and after 6 hours of adherence, 3 ¥ 105 T
cellswereadded.Threedifferent conditionswereanalyzed:
1) baseline (unstimulated T cells); 2) brefeldin treated
(6 hr before acquisition in the cytometer), plus phorbol
myristateacetate (PMA)and ionomycin (4 hrbeforeacqui-
sition); and 3) T cells stimulated with plate-bound anti-
CD3 (10 mg/mL) and soluble anti-CD28 (1 mg/mL)
monoclonal antibodies (MoAbs; BD Biosciences). After 2
days of coculture, CD4+ T cells were analyzed by flow
cytometry after stainingwith the following combination of
MoAbs: CD25-FITC/interferon (IFN)-g-PE/CD4-PerCP-
Cy5.5/CD40L-APC. For intracytoplasmic staining of IFN-g
and CD40L, a fixation and permeabilization stain kit
(IntraStain, Dako Cytomation, Glostrup, Denmark) was
used following the manufacturer’s instructions.
For proliferation assays we cultured 5 ¥ 104 MSCs per
well, and after 6 hours of adherence, 5 ¥ 105T cells per well
were added. Two different conditions were used for this
analysis: 4) baseline (unstimulated T-cells) and 5) T cells
stimulated with plate-bound anti-CD3 (10 mg/mL) and
soluble anti-CD28 (1 mg/mL) MoAbs (BD Biosciences).
After 5 days of coculture, two studies were performed: cell
cycle analysis andPKHstaininganalysis.Cell cycle analysis
with propidium iodide (PI) staining was performed
by flow cytometry after staining with CD2/CD3/CD5/
CD7-FITC/PIPerCP-Cy5.5. For PI staining, a DNA reagent
kit (CycleTest Plus, Becton Dickinson, Erembodegem,
Belgium) was used following the manufacturer’s instruc-
tions.T cellswere stainedwithPKH-67onDay0andstimu-
lated with plate-bound anti-CD3 (10 mg/mL) and soluble
anti-CD28 (1 mg/mL) MoAbs. T cells cultured for 5 days
(whether or not in the presence of MSCs) were collected;
stained with CD25-PE, 7-aminoactinomycin, and CD3-
APCMoAbs; and analyzed by flow cytometry.
Paint-A-Gate software was used to calculate the per-
centage and mean fluorescence channel (MFC) of acti-
vated T-Ly (positive cells for CD25, IFN-g, and CD40L);
ModFit software was also used to calculate the percentage
of resting and proliferatingT cells in the cell cycle analysis.
Paint-A-Gatesoftwarewasused tocalculate thepercentage
of proliferating activated T cells (PKHdimCD25+), nondi-
vided activatedT cells (PKHhighCD25+), andnonactivatedT
cells (PKHhighCD25-) amongviableTcells.ModFit software
was also used to calculate the percentage of resting and
proliferating cells.
Differentiation assays
To induce osteogenic differentiation, cells were replated
at 6000 cells/cm2 and cultured for 3 weeks in a-MEM
with 10 mmol/L b-glycerophosphate (Sigma), 0.2 mmol/L
ascorbic acid (Sigma), 0.1 mmol/L dexamethasone
(Sigma), 10% FCS (Biochrom, Berlin, Germany), and 1%
pen/strep. After 21 days cells were analyzed by alkaline
phosphatase and alizarin red staining. Adipogenic differ-
entiation was induced by culturing confluent MSCs in
a-MEM with 50 mmol/L indomethacin (Sigma),
0.5 mmol/L isobutyl-methylxanthine (Sigma), 1 mmol/L
dexamethasone (Sigma), 10% FCS, and 1% pen/strep for
21 days. Oil Red-O staining was performed to identify the
adipocyte cells. To induce condrogenic differentiation,
2 ¥ 105 cells were placed in a 15-mL conical tube to allow
aggregation of the cells in amicromass suspension culture
and kept for 21 days in DMEM-HG (DMEM with 4 g/L
glucose; Gibco) supplemented with 1% universal culture
supplement (ITS+ Premix, BD Biosciences; consisting of
6.25 mg/mL insulin, 6.25 mg/mL transferrin, 6.25 ng/mL
selenious acid, 1.25 mg/mL serum albumin [Sigma], and
5.35 mg/mL linoleic acid), 100 mg/mL sodium pyruvate,
50 mg/mL ascorbate-2-phosphate, 0.1 mmol/L dexam-
ethasone (Sigma), 500 ng/mL BMP6, 10 ng/mL trans-
forming growth factor-b3 (TGF-b3), and 1% pen/strep.
After 3 weeks, differentiation was analyzed by staining the
micromasses with toluidine blue in 5-mm sections.
Statistical analysis
Median values and ranges were calculated for each vari-
able. To explore the significance in the differences found
between the different groups a normality test was per-
formed. Normally distributed samples were compared
using the analysis of variance followed by post hoc test
while a Kruskal-Wallis test was used for samples that did
not fit a normal distribution. Paired-sample t tests were
performed to compare the effect of MSCs on
T-lymphocyte activation and proliferation within the dif-
ferent types of culture. Computer software (SPSS 15.0,
SPSS, Inc., Chicago, IL) was used. Differences were con-
sidered to be significant when p values were less than
0.05.
RESULTS
To compare the effects of the differentmedia supplements
on cell growth and characteristics of BM-MSCs,
BM-derived MNCs from eight different donors were
plated in parallel using four different culture conditions
(seeMaterials andMethods). PLwas obtained for a pool of
at least 10 different donors and used for cultures. PLT con-
centration from each donor ranged between 1 ¥ 109 and
2 ¥ 109 per mL. Cultures were maintained until P4 when
they were terminated (median number of days in culture
for all four conditions was 29  4). Neither the number of
population doublings nor the calculated cumulative
number of MSCs after P4 (Table 1 and Fig. 1) were statis-
tically different between the various culture media. The
addition of bFGF to media with PL did not significantly
increase the number of cells obtained in the culture. The
times taken to reach both the P4 and MSC duplication
period were not significantly different between the
various media. Interestingly, duplication time increased
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throughout all cultures, being significantly longer after P3
regardless of the media used.
MSC surface phenotype and differentiation
capacity
The surface phenotype of MSCs cultured under the four
different conditions was analyzed by flow cytometry at P1
to P4; the phenotypes were similar and in agreement with
previous reports.5,7 As shown in Fig. 2, MSCs were positive
for CD73, CD90, and CD44 and did not express CD34 and
CD45 (using the mean fluorescence intensity as criteria).
Expression of CD45 was detected at P1 and P2, consistent
with hematopoietic contamination that disappears after
P3 (data not shown). MSCs cultured in human serum had
a higher expression of CD45 and a lower expression of
CD73 and CD90 at P1, although the differences were not
significant (data not shown).
Differentiation to osteogenic, adipogenic, and con-
drogenic cells was induced with P4 MSCs grown in the
different media. As shown in Fig. 3, trilineage differentia-
tion of MSCs was observed in all cases as determined by
alkaline phosphatase activity and alzarin red, Oil Red-O,
and proteoglycans staining (toluidine blue), respectively.
Immunologic assays
To confirm that MSCs expanded with human serum (HS-
MSC) and PL with bFGF (PL-MSC) are as good as MSCs
expanded with FCS (FCS-MSC), not only in terms of
expansion and cell growth but also in terms of immuno-
suppression properties, we performed at least five experi-
ments coculturing MSCs and T lymphocytes under
TABLE 1. Population doubling and doubling time for the four different media*
Medium
P1-P2 P2-P3 P3-P4
PD DT (hr) PD DT (hr) PD DT (hr)
Human serum 3.95  1.64 36.44  15.20 6.49  2.63 56.8  23.05 7.69  2.9 112.02  45.44†
PL + bFGF 4.04  1.52 35.66  13.51 7.18  1.49 41.37  8.58 8.97  2.26 101.47  25.64†
PL 3.92  1.26 36.77  11.9 7.09  1.75 45.39  11.23 8.20  2.35 129.47  37.20†
FCS 3.86  1.09 37  10.44 7.09  1.50 45.05  9.53 8.33  1.22 115.60  17.06†
* Values represent the mean  SD. p Values were not significant between the different media.
† p < 0.05 in comparison with DT between P1-P2 and P2-P3.

























Fig. 1. Calculated cumulative cell counts of MSCs cultured from P0 to P4, in the different conditions. () human serum; (H17009) PL; ( )
PL + bFGF; (¥) FCS. Results are expressed as the mean number of MSCs/107 plated MNC cells calculated from data obtained from
eight BM donors.
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different conditions (with or without stimulation of T
cells) and analyzed the effect of MSCs on the activation
pattern (measured by flow cytometry) and proliferation
(evaluated by cell cycle analysis and PKH assays) of T cells.
Activation pattern in T cells (CD25, IFN-g, and CD40L)
Among T cells stimulated with anti-CD3/anti-CD28, the
presence of MSCs significantly influenced the expression
of the activation marker CD40L. Accordingly, the expres-
sion of CD40L was significantly reduced whenT cells were
cultured with MSCs: the MFC of CD40L was 49 in T cells
stimulated in the absence of MSCs (T cells alone) versus
19 in T cells plus HS-MSCs (p = 0.015), 31 in T cells plus
FCS-MSCs (p = 0.02), and 24 in T cells plus PL-MSCs
(p = 0.009). In addition, 50% ofT cells were CD40L positive
after stimulation in the absence ofMSCs compared to 17%
upon coculture with HS-MSCs (T cells plus HS-MSCs;
p = 0.002), 31% for T cells plus FCS-MSCs (p = 0.004), and
21% (p < 0.001) for T cells plus PL-MSCs, respectively.
Interestingly, HS-MSCs displayed themost intense inhibi-
tion of CD40L expression compared to PL-MSCs or FCS-
MSCs (Fig. 4A: the MFC of CD40L was 19 among T cells
plus HS-MSCs versus 32 among T cells plus FCS-MSCs
(p = 0.01) and 26 among T cells plus PL-MSCs (p = 0.03);
the percentage of CD40L-positiveT cells was 17% inT cells
plus HS-MSCs versus 33% in T cells plus FCS-MSCs
(p = 0.002) and 23% in T cells plus PL-MSCs, respectively
(p = 0.1). Similar results were obtained for PMA-
ionomycin–stimulated T cells (data not shown).
Regarding IFN-g production, among PMA-
ionomycin–stimulated T cells the addition of MSCs to the
culture decreased the production of this cytokine in terms
of percentage and MFCs irrespective of the medium used
for their expansion, although a trend toward a higher
inhibitory effect was also observed for HS-MSCs (Fig. 4B):
12% of stimulated T cells produced IFN in the absence of
MSC versus 5% for T cells plus HS-MSCs (p = 0.01), 7% for
T cells plus FCS-MSCs (p = 0.04), and 7% for T cells plus
PL-MSCs (p = 0.03), respectively (Fig. 4B).
The MFC of IFN-g was 132 in T cells stimulated in the
absence of MSCs (T cells alone) versus 58, 89, and 85 in T
cells plus HS-MSCs (p = 0.01), T cells plus FCS-MSCs
(p = 0.09), and T cells plus PL-MSCs (p = 0.02), respec-
tively. Upon comparing the effect of the different culture
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Fig. 2. FACS analysis of hMSC culture in the four different media.
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media, we observed that MSCs cultured with autologous
serum decreased the percentage of IFN-g producing T
cells more efficiently than MSC cultured with FCS
(p = 0.03 for percentage of positive cells and p = 0.03 for
MFCs) and similarly to PL (p = 0.09 for percentage of
positive cells and p = 0.05 for MFCs), respectively. Similar
results were obtained for anti-CD3 plus anti-CD28–
stimulated T cells (data not shown). No significant differ-
ences were observed in terms of CD25 expression among
stimulated T cells in the absence or presence of MSCs
(Fig. 4C).
Proliferation assays (cell cycle)
Proliferation assays showed a significant inhibition of cell
cycle among T cells cocultured with MSCs. Accordingly,
MSCs decreased the percentage of T cells in phase S and
G2/M irrespective of the culture medium used for their
expansion (Fig. 5). Similar results were observed when we
analyzed proliferation with PKH-67 staining, showing that
in the presence of MSCs, T cells were in resting state after
stimulation compared to proliferating state when T cells
were not cultured in the presence of MSCs (data not
shown).
DISCUSSION
In the past few years several clinical trials have been
devoted to exploring the efficacy and safety of MSC-
based therapy for different diseases (http://www.
clinicaltrials.gov). FCS has been traditionally used to
expand MSCs, but the administration of animal products
































Fig. 3. Representative photographs of MSCs expanded in the presence of human serum (HS), FCS, PL, and PL with bFGF
(PL + bFGF) and induced to differentiate into osteogenic, condrogenic, and adipogenic cells. (A-D) Differentiation into adipocytes is
revealed by the formation of lipid droplets (stained with Oil Red-O staining). (E-L) Differentiation into osteoblasts is demonstrated
by the histologic detection of calcium deposition stained with Alzarin red staining (E-H) and alkaline phosphatase activity (blue
reaction product; I-L). Differentiation to condrogenic cells is demonstrated by histologic detection of extracellular matrix (meta-
chromatic) of proteoglycan (toluidine blue staining). Magnification 10¥.
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still unidentified zoonosis. In addition, when expanded in
FCS containing medium, hMSCs have been implicated in
anaphylactic or arthuslike immune reactions.19 Although
a protocol has been described that successfully removes at
least 99.99% of all FCS contamination from hMSCs
expanded in 20% FCS,20 the risk of disease transmission
still remains. In consequence, several countries have
restricted or placed warnings on the clinical use of cell
therapy products prepared in the presence of FCS. In view
of these considerations, different studies have focused on
the identification of a serum-free medium appropriate for
the growth of the large number of MSCs required for clini-
cal application. In this regard, the use of PL or human
serum as medium supplements represents interesting
alternatives to FCS.
PL is an allogeneic clinical-grade product obtained
from blood donors. Human PL enriched in PLT-rich
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Fig. 4. Representative case on picture of five performed. (A) Dot plot showing the activation pattern in T cells stimulated with anti-
CD3/anti-CD28 plus HS-MSCs, FCS-MSCs, or PL-MSCs. (B) The expression of CD40L was significantly reduced when T cells were
stimulated in the presence of MSCs: percentage of CD40L-positive T cells being 50, 17, 31, and 21% among T lymphocytes cocul-
tured without MSCs, with HS-MSCs, FCS-MSCs, and PL-MSCs, respectively. (C) Dot plot representing IFN-g production among anti-
CD3/anti-CD28–stimulated T cells in the absence or presence of the different types of MSCs: percentage of IFN-g–positive T cells
was 12, 5, 7, and 7%, respectively, among T lymphocytes cocultured without MSCs, with HS-MSCs, FCS-MSCs, and PL-MSCs,
respectively.
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epidermal growth factor, and bFGF, which are growth
factors secreted by the PLTs required for MSC culture.21,22
Although some studies have indicated that the content of
growth factors varies according to PL concentration,
preparation mode, and so forth,23 it has also been shown
that the concentration of PLT-derived growth factor-AB,
TGF-b, bFGF, and vascular endothelial growth factor is
higher in PL than in many lots of FCS.10 Moreover, several
studies have already shown that it is possible to expand
MSCs with PL8,10 and that these MSCs cultured under
laboratory-scale conditions maintain their differentiation
properties and immunosuppressive activity.10
Human autologous serum would be the safest
choice, since it would avoid the exposure not only to FCS
but also to allogeneic products such as PL or allogeneic
serum. The feasibility of culturing MSCs in medium
supplemented with human serum only has been previ-
ously demonstrated.13-15 Nevertheless, the use of alloge-
neic human serum has resulted in MSC growth arrest
and death in some studies.20 Similarly, Stute and col-
leagues15 have reported that in media supplemented with
autologous human serum, MSCs showed normal growth
only early on during ex vivo culture. After 6 weeks they
formed clusters and eventually died. Most clinical trials
require between 0.5 ¥ 106 and 5 ¥ 106/kg MSCs,24-27 so the
achievement of this amount is a key factor for the
success of any protocol: autologous serum could not
therefore be considered as a general substitute for FCS,
the amount of serum available being a key limiting
factor. In this regard, from one blood donation of
500 mL, a maximum of 200 mL serum can be obtained,
that is, supplementing medium with 10% human serum
yields 2 L of expansion medium, which should be
enough for a 2- to 3-week expansion period. We have
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0 40 80 120 160
A
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B
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Fig. 5. Cell cycle analysis of a representative case from the five performed, assessed using PI and flow cytometry quantification in
anti-CD3/anti-CD28–stimulated T cells after coculture without or with the different types of MSCs decreased the percentage of cells
in phase S and G2/M increasing the percentage of cells in phase G0/G1, independent of the culture medium used (A = stimulated T
cells without MSCs; B = plus HS-MSCs; C = plus FCS-MSCs; and D = plus PL-MSCs; p  0.05 in all comparisons).
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previously reported a method for obtaining large
amounts of autologous serum suitable for culture at a
clinical scale (skeletal myoblasts),18 which would allow us
to obtain the amount of autologous serum required for
sufficient expansion of MSCs.
In this study, the growth, immunophenotype, differ-
entiation potential, and immunomodulatory properties
were compared between four media:
1. 10% FCS with 1 ng/mL bFGF (FCS medium);
2. 10% human serumwith 1 ng/mL bFGF (HSmedium);
3. 5% PL medium; and
4. PL with 1 ng/mL bFGF (PL plus bFGF medium).
Immunophenotypically, MSCs displayed a similar
pattern irrespective of the medium used for culture.
Accordingly, no expression of CD34 and CD45 was
observed in any case and expression of CD44, CD73, and
CD90 at the end of the culture (25-30 days) was similar in
all four conditions.28 Similarly, the different culture con-
ditions had the same osteogenic, adipogenic, and chon-
drogenic potential. These results are in accordance with
those reported by Doucet and coworkers and with our
previous study9,10 where we observed that MSCs
expanded in the presence of PL retained their ability to
differentiate into osteogenic, adipogenic, and chondro-
genic lineages.
One of the most interesting properties of hMSCs for
transplantation is their immunomodulating function,
which has shown promising results in the clinical setting
for treating GVHD. In this study, we demonstrate that
MSCs expanded with human serum or PL are at least as
immunosuppressive in vitro as MSCs expanded with
FCS. Furthermore, our results suggest that MSCs
expanded with human serum or PL induce an even more
intense inhibition of CD40L expression and IFN-g pro-
duction compared to FCS-MSCs. These results are in
accordance with those previously reported by Lange and
colleagues29 and suggest that FCS may worsen the immu-
nomodulatory capacity of MSCs. In a previous study,
Bernardo and coworkers8 showed that, compared to
PL-MSC, FCS-MSCs were more efficient in suppressing
alloantigen-induced lymphocyte proliferation and IFN-g
production. Perhaps the different time points (hours vs. 2
days) and methods used for analysis may explain these
differences.
Finally, we found that, in terms of MSC duplication,
the four media were equivalent, although the growth with
autologous serum was slightly slower. In clinical practice
one additional duplication would bring an important
advantage: in the same time it would be possible to obtain
double the number of MSCs. In conclusion, PL or auto-
logous serum could offer an alternative to the use of FCS
in MSC expansion for clinical use maintaining the same
growth potential, phenotype, immunomodulatory prop-
erties, and differentiation potential.
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